Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858023 | 1.00 | MEN1 (0.32) | MEN1MAPTKMT2ANPSR1ACACB | |
| SCHEMBL12628643 | 0.81 | ACACB (0.33) | MEN1MAPTKMT2ANPSR1ACACB | |
| SCHEMBL12628828 | 0.79 | — | — | |
| SCHEMBL1856209 | 0.70 | KMT2A (0.49) | MAPTKMT2A | |
| SCHEMBL1856211 | 0.70 | KMT2A (0.49) | MAPTKMT2A | |
| SCHEMBL20689758 | 0.69 | ACACB (0.41) | ACACB | |
| SCHEMBL11437321 | 0.67 | CYP3A4 (0.45) | MEN1MAPTKMT2ANPSR1ACACB | |
| SCHEMBL22221938 | 0.65 | ACACB (0.38) | MEN1MAPTKMT2AACACB | |
| SCHEMBL1622661 | 0.64 | MAPT (0.43) | MEN1MAPTKMT2ANPSR1ACACB | |
| SCHEMBL6967939 | 0.64 | RAB9A (0.42) | MEN1MAPTKMT2ANPSR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | F2R, F2RL1, F2RL3 | MEN1 2057/4885MAPT 3412/4885KMT2A 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.